Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2021, it operated three cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Global Cord Blood in a report on Friday, June 3rd. They issued a "strong-buy" rating for the company.
Global Cord Blood Trading Up 1.2 %
Shares of Global Cord Blood stock traded up $0.03 during trading hours on Friday, reaching $2.62. 75 shares of the company's stock were exchanged, compared to its average volume of 121,939. The firm has a market capitalization of $318.46 million, a price-to-earnings ratio of 4.05 and a beta of 0.14. The company has a fifty day moving average of $2.80 and a 200-day moving average of $3.33. Global Cord Blood has a 52-week low of $2.03 and a 52-week high of $5.50.
Global Cord Blood (NYSE:CO - Get Rating) last issued its earnings results on Tuesday, July 5th. The medical research company reported $0.14 earnings per share (EPS) for the quarter. Global Cord Blood had a net margin of 40.29% and a return on equity of 10.63%. The firm had revenue of $46.88 million for the quarter.